Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Figures & data

Table 1 Patient Demographics of the Entire Study Population (n = 53) or According to Treatment Received (n = 59 Courses of Therapy)

Variable		N	All Patients% (or Average ± SD)	Mepolizumab (n = 23)	Benralizumab (n = 12)	Omalizumab (n=24)
Age (years)		53	51.1 ± 16.5	53.8 ± 17.6	46.0 ± 13.9	51.4 ± 15.6
Gender	Male	26	49	9 (39%)	3	15
	Female	27	51	14 (61%)	9	9
BMI		52	30.2 ± 5.0	30.7 ± 5.3	29.5 ± 6.0	30.0 ± 4.4
Diagnosis	Eosinophilic asthma with/without allergies	38	71.7	23 (100%)	11	10
	Allergic	15	28.3	0 (0%)	1	14
Smoker	Never smoked	37	69.8	18 (78%)	9	15
	Ex-smoker	16	30.2	5 (22%)	3	9
Decreased number of exacerbations	Yes	21		1 (4%)	3	17
	No	38		22 (96%)	9	7

Figure 1 Changes in ACQ-5 scores over time for patients receiving (A) mepolizumab and benralizumab and (B) omalizumab. ****p < 0.0001.

Figure 2 Changes in raw PEFR and FEV₁ scores over time for patients receiving (A and C) mepolizumab and benralizumab and (B and D) omalizumab.

Table 2 Patient Demographics According to Treatment Received

Variable		Mepolizumab (n = 23)	Benralizumab (n = 12)	Omalizumab (n = 24)
Age (years)		53.8 ± 17.6	46.0 ± 13.9	51.4 ± 15.6
Gender	Male	9 (39%)	3	15
	Female	14 (61%)	9	9
BMI		30.7 ± 5.3	29.5 ± 6.0	30.0 ± 4.4
Diagnosis	Allergic and eosinophilic	23 (100%)	11	10
	Allergic	0 (0%)	1	14
Smoker	Never smoked	18 (78%)	9	15
	Ex-smoker	5 (22%)	3	9
Decreased number of exacerbations	Yes	1 (4%)	3	17
	No	22 (96%)	9	7

Figure 3 Percentage changes in PEFR and FEV₁ scores from baseline over time for patients receiving (A and C) mepolizumab and benralizumab and (B and D) omalizumab.